{
    "Trial Acronym": {
        "template": {
            "long_name": "Enter Trial Acronym",
            "short_name": "Trial Acronym",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Acronym or abbreviation used publicly to identify the clinical trial. Delete this line from the table if not applicable."
            ]
        },
        "technical": {
            "name": "Trial Acronym",
            "data_type": "Text",
            "definition": "C94108\nFor review purpose, see definition of the controlled terminology below:\nAcronym or abbreviation used publicly to identify the clinical trial.",
            "guidance": "Acronym or abbreviation used publicly to identify the clinical trial. Delete this line from the table if not applicable.",
            "conformance": "Optional ",
            "cardinality": "One to one",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier\nConcept: C94108",
            "repeating": "No",
            "ct": []
        }
    },
    "Sponsor Protocol Identifier": {
        "template": {
            "long_name": "Enter Sponsor Protocol Identifier",
            "short_name": "Sponsor Protocol Identifier",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "A unique alphanumeric identifier for the trial, designated by the Sponsor."
            ]
        },
        "technical": {
            "name": "Sponsor Protocol Identifier",
            "data_type": "Text",
            "definition": "C132351\nFor review purpose, see definition of the controlled terminology below: \nA unique code assigned by the Sponsor that identifies a specific protocol. ",
            "guidance": "A unique alphanumeric identifier for the trial, designated by the Sponsor.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "Title page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: C132351\nNote: Must have at least One Character May not be (null)",
            "repeating": "No",
            "ct": []
        }
    },
    "Version Number": {
        "template": {
            "long_name": "Enter Version Number",
            "short_name": "Version Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "For use by the Sponsor at their discretion."
            ]
        },
        "technical": {
            "name": "Version Number",
            "data_type": "Text",
            "definition": "C181232\nFor review purpose, see definition of the controlled terminology below:\nA string of numerals that uniquely identifies a specific version of a study protocol.",
            "guidance": " use by the Sponsor at their discretion.",
            "conformance": "Optional ",
            "cardinality": "One to one, Protocol Identifier",
            "relationship": "Title Page",
            "value": "Number",
            "business_rules": "Value Allowed: Yes\nRelationship: , Protocol Identifier\nConcept: C181232",
            "repeating": "No",
            "ct": []
        }
    },
    "Version Date": {
        "template": {
            "long_name": "Enter Version Date",
            "short_name": "Version Date",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "For use by the Sponsor at their discretion."
            ]
        },
        "technical": {
            "name": "Version Date",
            "data_type": "Date",
            "definition": "C93813\nFor review purpose, see definition of the controlled terminology below\nThe date on which the document is versioned.",
            "guidance": "or use by the Sponsor at their discretion.",
            "conformance": "Optional ",
            "cardinality": "One to one; one to Version Number",
            "relationship": "Title page",
            "value": "Date Format ",
            "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: C93813",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial Short Title": {
        "template": {
            "long_name": "Enter Trial Short Title",
            "short_name": "Trial Short Title",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Short title should convey in plain language what the trial is about and should be suitable for use as \u201cBrief Title\u201d or \u201cTitle in Plain Language\u201d in global clinical trial registries. It can also be suitable for use with informed consents and ethics committee submissions."
            ]
        },
        "technical": {
            "name": "Trial Short Title",
            "data_type": "Text",
            "definition": "C132345\nFor review purpose, see definition of the controlled terminology below\nThe short descriptive name for the protocol.",
            "guidance": "Short title should convey in plain language what the trial is about and should be suitable for use as \u201cBrief Title\u201d or \u201cTitle in Plain Language\u201d in global clinical trial registries. It can also be suitable for use with informed consents and ethics committee submissions.",
            "conformance": "Optional",
            "cardinality": "One to one, One to Protocol identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: C132345",
            "repeating": "No",
            "ct": []
        }
    },
    "Sponsor Name": {
        "template": {
            "long_name": "Enter Sponsor Name",
            "short_name": "Sponsor Name",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Sponsor Name",
            "data_type": "Text",
            "definition": "C70793\nFor review purpose, see definition of the controlled terminology below\nAn individual, company, institution, or organisation that takes responsibility for the initiation, management, and/or financing of a clinical study. [After ICH E6, WHO, 21 CFR 50.3 (e), and after IDMP]",
            "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
            "conformance": "Required ",
            "cardinality": "One to one; One to Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier\nConcept: C70793",
            "repeating": "No",
            "ct": []
        }
    },
    "Sponsor Legal Address": {
        "template": {
            "long_name": "Enter Sponsor Legal Address",
            "short_name": "Sponsor Legal Address",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Sponsor Legal Address",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the trial Sponsor.",
            "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
            "conformance": "Required ",
            "cardinality": "One to one, One to Sponsor Name",
            "relationship": "Title Page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Name\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Local Sponsor Name": {
        "template": {
            "long_name": "Enter Local Sponsor Name",
            "short_name": "Local Sponsor Name",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Local Sponsor Name",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence.",
            "guidance": "In some countries, the clinical trial Sponsor may be the local affiliate company (or designee). In such cases, indicate this in the Sponsor Name and Address Field.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Name and Address; Many to Sponsor Name",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Name and Address; Sponsor Name; Country\nConcept: CNEW",
            "repeating": "Yes, repeatable for each Local Sponsor Name",
            "ct": []
        }
    },
    "Local Sponsor Address": {
        "template": {
            "long_name": "Enter Local Sponsor Address",
            "short_name": "Local Sponsor Address",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "In some countries, the clinical trial Sponsor may be the local affiliate company (or designee). In such cases, indicate this in the Local Sponsor Name and Address Field."
            ]
        },
        "technical": {
            "name": "Local Sponsor Address",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence.",
            "guidance": "In some countries, the clinical trial Sponsor may be the local affiliate company (or designee). In such cases, indicate this in the Sponsor Local Name and Address Field.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Local Sponsor; One to Country ",
            "relationship": "Title page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Local Sponsor, Country\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Device Manufacturer Name": {
        "template": {
            "long_name": "Enter Device Manufacturer Name",
            "short_name": "Device Manufacturer Name",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Device Manufacturer Name",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe organisation defined as being responsible for creating the device as stated on the package in which the product is supplied.",
            "guidance": "Manufacturer name and address information is required only for protocols that include investigational device(s) and should not be included for other protocols. Include the manufacturer address only if the manufacturer is different than the Sponsor listed above.\nAdd additional fields as needed if multiple investigational devices will be used in the trial. Delete this line if not applicable.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Protocol Identifier; One to Sponsor Name",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier; Sponsor Name\nConcept: CNEW",
            "repeating": "Yes, repeatable for each device manufacturers",
            "ct": []
        }
    },
    "Device Manufacturer Address": {
        "template": {
            "long_name": "Enter Device Manufacturer Address",
            "short_name": "Device Manufacturer Address",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Add additional fields as needed if multiple investigational devices will be used in the trial. Delete this line if not applicable."
            ]
        },
        "technical": {
            "name": "Device Manufacturer Address",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the device manufacturer.",
            "guidance": "Manufacturer name and address information is required only for protocols that include investigational device(s) and should not be included for other protocols. Include the manufacturer address only if the manufacturer is different than the Sponsor listed above.\nAdd additional fields as needed if multiple investigational devices will be used in the trial. Delete this line if not applicable.",
            "conformance": "Optional",
            "cardinality": "One to One; One to Device Manufacturer Name",
            "relationship": "Title Page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Device Manufacturing Name\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "EU CT Number": {
        "template": {
            "long_name": "EU CT Number",
            "short_name": "EU CT Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "EU CT Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the Clinical Trials Information System (CTIS) of the European Medicines Agency.",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Protocol Identifier",
            "relationship": "Title Page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes; EU CT number: yyyy-5xxxxx-xx with YYYY corresponding to a year i.e. 2024 and x being an integer\nRelationship: Heading; Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "IDE Number": {
        "template": {
            "long_name": "IDE Number",
            "short_name": "IDE Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "IDE Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial under an Investigational Device Exemption (IDE) application, as assigned by the US Food and Drug Administration.",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Protocol Identifier",
            "relationship": "Title Page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "jRCT Number": {
        "template": {
            "long_name": "jRCT Number",
            "short_name": "jRCT Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "jRCT Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the Japan Registry for Clinical Trials (JRCT) of the Ministry of Health, Labour and Welfare (MHLW) in Japan.",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Protocol Identifier",
            "relationship": "Title Page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "NCT Number": {
        "template": {
            "long_name": "NCT Number",
            "short_name": "NCT Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "NCT Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the protocol registration and results (PRS) system of the US National Library of Medicine.",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Protocol Identifier",
            "relationship": "Title Page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: CNEW ",
            "repeating": "No",
            "ct": []
        }
    },
    "NMPA IND Number": {
        "template": {
            "long_name": "NMPA IND Number",
            "short_name": "NMPA IND Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "NMPA IND Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial under an Investigational New Drug (IND) application, as assigned by the Chinese National Medicinal Products Administration (NMPA).",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to rotocol Identifier",
            "relationship": "Title Page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Amendment Summary": {
        "template": {
            "long_name": "Amendment Summary",
            "short_name": "Amendment Summary",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Describe key changes briefly. Changes which are included in the amendment but unrelated to the key changes do not need to be described here."
            ]
        },
        "technical": {
            "name": "Amendment Summary",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA short narrative representation describing the changes introduced in the current version of the protocol.",
            "guidance": "Describe key changes briefly. Changes which are included in the amendment but unrelated to the key changes do not need to be described here. ",
            "conformance": "Conditional: if there is an amendment",
            "cardinality": "One to Amendment identifier",
            "relationship": "Amendment Details",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details; Amendment Identifier, Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Description of Change": {
        "template": {
            "long_name": "Enter Description of Change",
            "short_name": "Description of Change",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "Description of Change",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the change introduced in the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional:  ",
            "cardinality": "Column Heading \nRow Content",
            "relationship": "12.3",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading and 12.3 Prior Protocol Amendment(s)\nConcept: CNEW",
            "repeating": "Yes, repeatable for every description of change",
            "ct": []
        }
    },
    "Brief Rationale for Change": {
        "template": {
            "long_name": "Enter Brief Rationale for Change",
            "short_name": "Brief Rationale for Change",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "Brief Rationale for Change",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe brief reason for the change introduced in the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional: ",
            "cardinality": "One to Column Heading\nRow description of change \nSection# and Name",
            "relationship": "12.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading Brief Rationale for Change and <Description of Change>\nConcept: CNEW",
            "repeating": "Yes, repeatable for every description of change",
            "ct": []
        }
    },
    "Primary and Secondary Objectives and Estimands": {
        "template": {
            "long_name": "Enter Primary and Secondary Objectives and Estimands",
            "short_name": "Primary and Secondary Objectives and Estimands",
            "optional": false,
            "section_number": "1.1.1",
            "section_title": "Primary and Secondary Objectives and Estimands",
            "instructions": []
        },
        "technical": {
            "name": "Primary and Secondary Objectives and Estimands",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA descriptive summary of the primary and secondary objectives and their associated estimands related to the trial.",
            "guidance": "Summarise the primary and secondary objectives and any associated estimands in natural, nontechnical (layperson) language. \nFor trials intended to estimate a treatment effect or test a hypothesis related to a treatment effect, include the primary and secondary objectives and any associated estimands using a nontechnical summary describing the objective and treatment effect of interest (estimand). \nFor other types of trials not intended to estimate a treatment effect or test a hypothesis related to a treatment effect, define trial objectives and describe additional information relevant to the clinical question(s) of interest (e.g., the endpoint(s) associated with each objective).\nFor trials with numerous objectives in which the description of objectives will exceed half a page, consider including the most important objectives and estimands in the synopsis and refer to Section 3 Trial Objectives and Associated Estimands, which covers the objectives and estimands in technical detail. For considerations on estimands, refer to ICH E9(R1).",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 1.1.1 Primary and Secondary Objectives and Estimands\nConcept: CNEW",
            "repeating": "Yes, Reuse <Primary Objective> and <Endpoint> for each Primary Objective from section 3.1, reuse <Secondary Objective and <ndpoint> for each Secondary Objective from section 3.2.",
            "ct": []
        }
    },
    "Number of Participants": {
        "template": {
            "long_name": "Enter Number of Participants",
            "short_name": "Number of Participants",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Number of Participants",
            "data_type": "Number",
            "definition": "C49692\nFor review purpose, see definition of the controlled terminology below\nThe planned number of participant be entered in a clinical trial.",
            "guidance": "State the expected number of participants to be assigned to trial intervention/enrolled. Indicate whether the number provided is the target or maximum number of individuals to be randomly assigned to trial intervention/enrolled",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Integer; <Number of Participants> participants will be",
            "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: C49692",
            "repeating": "No",
            "ct": []
        }
    },
    "alternate description of planned duration of trial intervention if duration will vary": {
        "template": {
            "long_name": "Enter alternate description of planned duration of trial intervention if duration will vary",
            "short_name": "alternate description of planned duration of trial intervention if duration will vary",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "alternate description of planned duration of trial intervention if duration will vary",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn alternative textual narrative for the planned duration of trial intervention.",
            "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
            "conformance": "Conditional: when an alternate description for planned duration of trial Intervention if the duration varies",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "text",
            "business_rules": "Value Allowed: Yes\nRelationship: Total duration of trial intervention for each participant:\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "alternate description of planned duration of trial participation if duration will vary": {
        "template": {
            "long_name": "Enter alternate description of planned duration of trial participation if duration will vary",
            "short_name": "alternate description of planned duration of trial participation if duration will vary",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "If necessary, include any clarifications or cross references to details in the main body of the protocol in the optional field below."
            ]
        },
        "technical": {
            "name": "alternate description of planned duration of trial participation if duration will vary",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn alternative narrative for the planned duration of trial participation.",
            "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
            "conformance": "Conditional: when an alternate description for planned duration of trial participation if duration will vary",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Total duration of planned duration of trial participation if duration will vary:\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Additional Description of Duration": {
        "template": {
            "long_name": "Enter Additional Description of Duration",
            "short_name": "Additional Description of Duration",
            "optional": true,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Additional Description of Duration",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative clarifying information regarding the length of time an individual usage of trial intervention or planned time in a trial.",
            "guidance": "If necessary, include any clarifications or cross-references to details in the main body of the protocol in the optional field below.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Duration\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Independent Committees": {
        "template": {
            "long_name": "Enter Independent Committees",
            "short_name": "Independent Committees",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Independent Committees",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn independent group of experts that has oversight over, and conducts periodic review of, specific trial activities.",
            "guidance": "Indicate whether any committee(s) will be reviewing data while the trial is ongoing, and the type of committee. Common examples include Data Monitoring Committee, Dose Escalation Committee, or Endpoint Adjudication Committee; describe others, if applicable. List independent committees in the space indicated. Other committees may be included in the separate space provided. Committees listed here should be fully described in Section 11.4.",
            "conformance": "Required",
            "cardinality": "One to many",
            "relationship": "1.1.2",
            "value": "Independent Data Monitoring Committee(C142578), Dose Escalation Committee(C78726), Endpoint Adjudication Committee(C78726), other (C17649), none(C41132) ",
            "business_rules": "Value Allowed: Yes, More than one committee can be selected\nRelationship: Independent Committees\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Independent Committee Name Response",
                    "definition": "A terminology value set relevant to the independent committee name responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C142578",
                    "preferred_term": "Independent Data Monitoring Committee",
                    "definition": "A committee established by the sponsor to assess at intervals the progress of a clinical trial, safety data, and critical efficacy variables and recommend to the sponsor whether to continue, modify, or terminate the trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Dose Escalation Committee",
                    "definition": "A type of safety monitoring committee that monitors dose escalation activities in first-in-human trials."
                },
                {
                    "ncit_code": "C78726",
                    "preferred_term": "Endpoint Adjudication Committee",
                    "definition": "An external committee whose purpose is to evaluate study data and decide whether a study endpoint or other criterion has been met."
                },
                {
                    "ncit_code": "C17649",
                    "preferred_term": "Other",
                    "definition": "Different than the one(s) previously specified or mentioned."
                },
                {
                    "ncit_code": "C41132",
                    "preferred_term": "None",
                    "definition": "No person or thing, nobody, not any."
                }
            ]
        }
    },
    "Other Committees": {
        "template": {
            "long_name": "Enter Other Committees",
            "short_name": "Other Committees",
            "optional": true,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "Delete \u201cOther Committees\u201d if not applicable."
            ]
        },
        "technical": {
            "name": "Other Committees",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA committee that is different than the one(s) previously specified or mentioned.",
            "guidance": "Delete \u201cOther Committees\u201d if not applicable.",
            "conformance": "Optional ",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Other Committees\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial Schema": {
        "template": {
            "long_name": "Enter Trial Schema",
            "short_name": "Trial Schema",
            "optional": false,
            "section_number": "1.2",
            "section_title": "Trial Schema",
            "instructions": []
        },
        "technical": {
            "name": "Trial Schema",
            "data_type": "Image; Text",
            "definition": "C93682\nFor review purpose, see definition of the controlled terminology below\nA diagram that outlines the decision points (e.g. randomisation, response evaluation) that define the different paths a participant could take through the trial.",
            "guidance": "The purpose of this section is to provide a visual depiction of the trial design, orienting users of the protocol to the key features of the design. The schema depicts the trial arms, the flow of individual participants through the progression of trial period(s)/epochs (such as screening, washout/run-in, intervention, and key milestones [e.g., randomisation, cross-over, end of treatment, end of study, post-treatment follow-up]). For complex trials, additional schemas may be added to describe activities or trial periods in greater detail.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.2",
            "value": "Image; Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 1.2 Trial Schema\nConcept: C93682",
            "repeating": "Yes, repeatable within Section",
            "ct": []
        }
    },
    "Schema Notes": {
        "template": {
            "long_name": "Enter Schema Notes",
            "short_name": "Schema Notes",
            "optional": true,
            "section_number": "1.2",
            "section_title": "Trial Schema",
            "instructions": []
        },
        "technical": {
            "name": "Schema Notes",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA brief written record describing the trial schematic.",
            "guidance": "The purpose of this section is to provide a visual depiction of the trial design, orienting users of the protocol to the key features of the design. The schema depicts the trial arms, the flow of individual participants through the progression of trial period(s)/epochs (such as screening, washout/run-in, intervention, and key milestones [e.g., randomisation, cross-over, end of treatment, end of study, post-treatment follow-up]). For complex trials, additional schemas may be added to describe activities or trial periods in greater detail.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 1.2 Trial Schema\nConcept: CNEW",
            "repeating": "Yes, repeatable and aligned with appropriate schema",
            "ct": []
        }
    },
    "Schedule of Activities": {
        "template": {
            "long_name": "Enter Schedule of Activities",
            "short_name": "Schedule of Activities",
            "optional": false,
            "section_number": "1.3",
            "section_title": "Schedule of Activities",
            "instructions": []
        },
        "technical": {
            "name": "Schedule of Activities",
            "data_type": "Table; Text; Image",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA standardised representation of planned clinical trial activities including interventions (e.g. administering drug, surgery) and study administrative activities (e.g. obtaining informed consent, distributing clinical trial material and diaries, randomisation) as well as assessments.",
            "guidance": "The schedule of activities must capture the procedures that will be accomplished at each trial visit, and all contact with participants, e.g., telephone contacts. This includes any tests that are used for eligibility, participant randomisation or stratification, or decisions on trial intervention discontinuation. Allowable windows should be stated for all visits and procedures. A tabular format is recommended.\nWhen applicable for studies with extensive sampling, e.g., serial PK sampling, a separate table may be added",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.3",
            "value": "Table; text; Image",
            "business_rules": "Value Allowed: Yes\nRelationship: 1.3 Schedule of Activities\nConcept: CNEW",
            "repeating": "Yes, repeatable for each Schedule of Activity if needed",
            "ct": []
        }
    },
    "Purpose of Trial": {
        "template": {
            "long_name": "Enter Purpose of Trial",
            "short_name": "Purpose of Trial",
            "optional": false,
            "section_number": "2.1",
            "section_title": "Purpose of Trial",
            "instructions": []
        },
        "technical": {
            "name": "Purpose of Trial",
            "data_type": "Text",
            "definition": "C146997\nFor review purpose, see definition of the controlled terminology below\nThe overall rationale, reason, or intention of the clinical trial.",
            "guidance": "Explain why the trial is needed, why the research questions being asked are important. Do not restate the objectives or estimands. Do not restate the IB; rather, cross reference to the IB as applicable to the description. ",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "2.1 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.1 Purpose of Trial\nConcept: C146997",
            "repeating": "No",
            "ct": []
        }
    },
    "Primary Objective": {
        "template": {
            "long_name": "Enter Primary Objective",
            "short_name": "Primary Objective",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective",
            "instructions": []
        },
        "technical": {
            "name": "Primary Objective",
            "data_type": "Text",
            "definition": "C85826\nFor review purpose, see definition of the controlled terminology below\nThe principle reason for performing a study in terms of the scientific questions to be answered by the analysis of data collected during the study.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to One, One to T Number 3.1.X, One to Estimand Characteristics Table, Primary Objective X, Protocol Identifier ",
            "relationship": "3.1.X",
            "value": "",
            "business_rules": "Value Allowed: Yes\nRelationship: 3.1.X Primary Objective \nConcept: C85826",
            "repeating": "\n",
            "ct": []
        }
    },
    "Population": {
        "template": {
            "long_name": "Enter Population",
            "short_name": "Population",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective",
            "instructions": []
        },
        "technical": {
            "name": "Population",
            "data_type": "Text",
            "definition": "C70833\nFor review purpose, see definition of the controlled terminology below\nThe population of patients targeted by the clinical question. This will be represented by the entire trial population, a subgroup defined by a particular characteristic measured at baseline, or a principal stratum defined by the occurrence (or non-occurrence, depending on context) of a specific intercurrent event.",
            "guidance": "List of key characteristics, such as demographic characteristics (e.g. age, sex) and clinical characteristics (e.g. prior therapies, symptoms, severity, biomarker status)",
            "conformance": "Conditional: If there is a population",
            "cardinality": "One to Row Heading, One to Exploratory Objective Table, Exploratory Objective X, Protocol Identifier ",
            "relationship": "3.3.X ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description; Table Estimand Characteristics, Exploratory (1\u2026n) Estimand\nConcept: C70833",
            "repeating": "\n",
            "ct": []
        }
    },
    "Treatment": {
        "template": {
            "long_name": "Enter Treatment",
            "short_name": "Treatment",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective",
            "instructions": []
        },
        "technical": {
            "name": "Treatment",
            "data_type": "Text",
            "definition": "C49236\nFor review purpose, see definition of the controlled terminology below\nThe treatment condition of interest and, as appropriate, the alternative treatment condition to which comparison will be made (referred to as \u201ctreatment\u201d through the remainder of this document). These might be individual interventions, combinations of interventions administered concurrently, e.g. as add-on to standard of care, or might consist of an overall regimen involving a complex sequence of interventions.",
            "guidance": "List of key aspects of treatment regimens in each study group, including at least investigational agents, dosage, and administration route",
            "conformance": "Conditional: If there is a ",
            "cardinality": "One to Row Heading, One Exploratory Objective Table, Project Identifier ",
            "relationship": "3.3.X ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description; Table Estimand Characteristics, Exploratory (1\u2026n) Estimand; Protocol Identifier\nConcept: C49236",
            "repeating": "\n",
            "ct": []
        }
    },
    "Endpoint": {
        "template": {
            "long_name": "Enter Endpoint",
            "short_name": "Endpoint",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective",
            "instructions": []
        },
        "technical": {
            "name": "Endpoint",
            "data_type": "Text",
            "definition": "C25212\nFor review purpose, see definition of the controlled terminology below\nThe variable to be obtained for each patient that is required to address the clinical question. The specification of the variable might include whether the patient experiences an intercurrent event",
            "guidance": "List of key characteristics, such as demographic characteristics (e.g. age, sex) and clinical characteristics (e.g. prior therapies, symptoms, severity, biomarker status)",
            "conformance": "",
            "cardinality": "One to Row Heading, One to Exploratory Objective Table, Project Identifier ",
            "relationship": "3.3.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description; Table Estimand Characteristics, Exploratory (1\u2026n) Estimand\nConcept: C25212",
            "repeating": "\n",
            "ct": []
        }
    },
    "Description of Intercurrent Event": {
        "template": {
            "long_name": "Enter Description of Intercurrent Event",
            "short_name": "Description of Intercurrent Event",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective",
            "instructions": []
        },
        "technical": {
            "name": "Description of Intercurrent Event",
            "data_type": "Text",
            "definition": "\nC188853\nFor review purpose, see definition of the controlled terminology below\nA textual description of the planned strategy to address intercurrent events.",
            "guidance": "Enter Description of Intercurrent Event",
            "conformance": "",
            "cardinality": "One to one or as many intercurrent event as available ",
            "relationship": "3.3.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Estimand Characteristics\nConcept: C188853",
            "repeating": "Yes, repeatable for each intercurrent event",
            "ct": []
        }
    },
    "Secondary Objective": {
        "template": {
            "long_name": "Enter Secondary Objective",
            "short_name": "Secondary Objective",
            "optional": false,
            "section_number": "3.2.1",
            "section_title": "{Secondary Objective}",
            "instructions": [
                "If a Secondary Objective has been entered:"
            ]
        },
        "technical": {
            "name": "Secondary Objective",
            "data_type": "Text",
            "definition": "C85827\nFor review purpose, see definition of the controlled terminology below\nThe secondary reason for performing a study in terms of the scientific questions to be answered by the analysis of data collected during the study.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one; T Number 3.2.X, One to Estimand  Table, Secondary Objective X, Protocol Identifier ",
            "relationship": "3.2.X ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 3.2.X Secondary Objective, Estimand Characteristics table\nConcept: C85827",
            "repeating": "\n",
            "ct": []
        }
    },
    "Exploratory Objective": {
        "template": {
            "long_name": "Enter Exploratory Objective",
            "short_name": "Exploratory Objective",
            "optional": false,
            "section_number": "3.3.1",
            "section_title": "{Exploratory Objective}",
            "instructions": [
                "If an Exploratory Objective has been entered: "
            ]
        },
        "technical": {
            "name": "Exploratory Objective",
            "data_type": "Text",
            "definition": "C163559\nFor review purpose, see definition of the controlled terminology below\nThe exploratory reason for performing a study in terms of the scientific questions to be answered by the analysis of data collected during the study.",
            "guidance": "State each exploratory objective. This should generally include documentation of associated exploratory endpoints. It may be helpful in some cases to describe precise estimands to provide clarity on what is being estimated.",
            "conformance": "Conditional: an exploratory objective is part of the trial",
            "cardinality": "One to T Number 3.3.X, One to Estimand Characteristic Table, Exploratory Objective X, Protocol Identifier ",
            "relationship": "3.3.X ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 3.3.X Exploratory Objective(s)\nConcept: C163559",
            "repeating": "\n",
            "ct": []
        }
    },
    "Method of Assignment to Trial Intervention": {
        "template": {
            "long_name": "Enter Method of Assignment to Trial Intervention",
            "short_name": "Method of Assignment to Trial Intervention",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": []
        },
        "technical": {
            "name": "Method of Assignment to Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe technique used to assign trial participants to a trial intervention or trial arm.",
            "guidance": "State the method of assignment to trial intervention the level and method of blinding that will be used with reference to Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding.\n",
            "conformance": "",
            "cardinality": "One to one",
            "relationship": "4.1 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Additional Description of Trial Design": {
        "template": {
            "long_name": "Enter Additional Description of Trial Design",
            "short_name": "Additional Description of Trial Design",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": []
        },
        "technical": {
            "name": "Additional Description of Trial Design",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn extra or further textual representation of the trial design.",
            "guidance": "",
            "conformance": "",
            "cardinality": "One to one",
            "relationship": "4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\n\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Stakeholder Input into Design": {
        "template": {
            "long_name": "Enter Stakeholder Input into Design",
            "short_name": "Stakeholder Input into Design",
            "optional": false,
            "section_number": "4.1.1",
            "section_title": "Stakeholder Input into Design",
            "instructions": []
        },
        "technical": {
            "name": "Stakeholder Input into Design",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe textual representation of the way in which trial stakeholders were consulted when determining the trial design.",
            "guidance": "If applicable, describe any stakeholder (e.g., patient, healthcare professional and patient advocacy groups) involvement in the design of the trial and any suggestions implemented",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "4.1.1 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1.1 Stakeholder Input into Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Overall Rationale for Trial Design": {
        "template": {
            "long_name": "Enter Overall Rationale for Trial Design",
            "short_name": "Overall Rationale for Trial Design",
            "optional": true,
            "section_number": "4.2",
            "section_title": "Rationale for Trial Design",
            "instructions": [
                "OR"
            ]
        },
        "technical": {
            "name": "Overall Rationale for Trial Design",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial design considerations that are different than the one(s) previously specified or mentioned.",
            "guidance": "N/A",
            "conformance": "Conditional: If Level 3 subheadings are not used",
            "cardinality": "One to one",
            "relationship": "4.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2 Rationale for Trial Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rationale for Duration": {
        "template": {
            "long_name": "Enter Rationale for Duration",
            "short_name": "Rationale for Duration",
            "optional": false,
            "section_number": "4.2.4",
            "section_title": "Rationale for Trial Duration",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Duration",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the trial duration.",
            "guidance": "Provide a rationale that the trial duration is appropriate for a reliable and relevant evaluation of the trial intervention per the trial objective(s).",
            "conformance": "Conditional: when  is not used",
            "cardinality": "One to one",
            "relationship": "4.2.",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2. Rationale for Duration\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rationale for Interim Analysis": {
        "template": {
            "long_name": "Enter Rationale for Interim Analysis",
            "short_name": "Rationale for Interim Analysis",
            "optional": false,
            "section_number": "4.2.6",
            "section_title": "Rationale for Interim Analysis",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Interim Analysis",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation for the analysis comparing intervention groups at any time before the formal completion of the trial, usually before recruitment is complete.",
            "guidance": "If applicable, provide a rationale for any interim analysis planned with respect to its purpose (e.g., stopping the trial early for efficacy or futility) and timing.",
            "conformance": "Conditional: when is not used",
            "cardinality": "One to one",
            "relationship": "4.2.",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.Rational for Interim Analysis\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rationale for Other Trial Design Aspects": {
        "template": {
            "long_name": "Enter Rationale for Other Trial Design Aspects",
            "short_name": "Rationale for Other Trial Design Aspects",
            "optional": false,
            "section_number": "4.2.7",
            "section_title": "Rationale for Other Trial Design Aspects",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Other Trial Design Aspects",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for additional trial design considerations that are different than the one(s) previously specified or mentioned.",
            "guidance": "Discuss rationale for any additional aspects of the design not addressed above.",
            "conformance": "Conditional: when  is not used ",
            "cardinality": "One to one",
            "relationship": "4.2.7 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.7 Rational for Other Trial Design Aspects\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial Stopping Rules": {
        "template": {
            "long_name": "Enter Trial Stopping Rules",
            "short_name": "Trial Stopping Rules",
            "optional": false,
            "section_number": "4.3",
            "section_title": "Trial Stopping Rules",
            "instructions": []
        },
        "technical": {
            "name": "Trial Stopping Rules",
            "data_type": "Text",
            "definition": "C142698\nFor review purpose, see definition of the controlled terminology below \nA criterion that, when met by the accumulating data, indicates that the trial can or should be stopped early to avoid putting participants at risk unnecessarily or because the intervention effect is so great that further data collection is unnecessary.",
            "guidance": "If applicable, describe any trial-specific stopping rules, including guidance on when the trial should be stopped for efficacy or safety reasons, when a cohort or dose escalation should be terminated, and/or when a given treatment arm should be terminated. If applicable, describe any rules that may result in a temporary pause of dosing and/or enrollment into the trial and criteria for restarting enrollment. Ensure that the trial stopping rules are aligned with the specifications that are described in Section 10.9 for Interim Analyses.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "4.3 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.3 Trial Stopping Rules\nConcept: C142698",
            "repeating": "No",
            "ct": []
        }
    },
    "Start of Trial": {
        "template": {
            "long_name": "Enter Start of Trial",
            "short_name": "Start of Trial",
            "optional": false,
            "section_number": "4.4",
            "section_title": "Start of Trial and End of Trial",
            "instructions": []
        },
        "technical": {
            "name": "Start of Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description containing a concise explanation, any local regulatory requirements and considerations, extensions, follow-up, and analysis for the trial start.",
            "guidance": "Define key timepoints in the trial, including trial start and end definitions. (e.g., a key timepoint definition for start of trial might be when the informed consent is signed by the first participant and a key timepoint definition for end of trial might be when participants are no longer being examined or the last participant\u2019s last trial assessment has occurred). Consider local regulatory requirements for these and other definitions (e.g., the first act of recruitment).\nIf appropriate, provide a cross-reference to Section 11.1 Early Site Closure.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "4.4 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.4 Start of Trial and End of Tria\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "End of Trial": {
        "template": {
            "long_name": "Enter End of Trial",
            "short_name": "End of Trial",
            "optional": false,
            "section_number": "4.4",
            "section_title": "Start of Trial and End of Trial",
            "instructions": []
        },
        "technical": {
            "name": "End of Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description containing a concise explanation, any local regulatory requirements and considerations, extensions, follow-up, and analysis for the trial end.",
            "guidance": "Define key timepoints in the trial, including trial start and end definitions. (e.g., a key timepoint definition for start of trial might be when the informed consent is signed by the first participant and a key timepoint definition for end of trial might be when participants are no longer being examined or the last participant\u2019s last trial assessment has occurred). If applicable, consider local regulatory requirements for these and other definitions (e.g., the first act of recruitment).\nIf appropriate, provide a cross-reference to Section 11.10 Early Site Closure.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "4.4 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.4 Start of Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Access to Trial Intervention after End of Trial": {
        "template": {
            "long_name": "Enter Access to Trial Intervention after End of Trial",
            "short_name": "Access to Trial Intervention after End of Trial",
            "optional": false,
            "section_number": "4.5",
            "section_title": "Access to Trial Intervention After End of Trial",
            "instructions": []
        },
        "technical": {
            "name": "Access to Trial Intervention after End of Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual representation containing information about whether and how trial participants have access to the trial interventions after the trial ends.",
            "guidance": "If applicable, describe any possibilities for access to trial intervention, if any, beyond completion of the trial. Planned extension trials, if described in Section 4.1 Description of Trial Design do not need to be repeated.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "4.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.5 Access to Trial Intervention After End of Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Description of Trial Population and Rationale": {
        "template": {
            "long_name": "Enter Description of Trial Population and Rationale",
            "short_name": "Description of Trial Population and Rationale",
            "optional": false,
            "section_number": "5.1",
            "section_title": "Description of Trial Population and Rationale",
            "instructions": []
        },
        "technical": {
            "name": "Description of Trial Population and Rationale",
            "data_type": "Text",
            "definition": "CNEW\nA narrative representation of the rationale for selection of trial population describing how the selected population can meet the trial objectives and how the enrolment criteria reflect the targeted populations.",
            "guidance": "Describe the population selected (e.g., healthy participants, adult participants, paediatric participants) and how the enrollment criteria reflect the populations that are likely to use the drug if approved. Specify the population age range (e.g., \u22643 months, \u226518 to \u226480 years old) including the time point at which qualification for age criteria is determined (e.g., at time of screening vs randomisation for paediatric trials). Specify any key diagnostic criteria for the population (e.g., \u201cacute lung injury\u201d, or a specific biomarker profile). If applicable, describe similar conditions or diseases and their differential diagnosis. \nProvide a rationale for the trial population ensuring that the population selected is well defined and clinically recognisable. Describe how the selected population can meet the trial objectives and how the enrollment criteria reflect the population of interest.\nIf the population targeted by a clinical question is based on a subset of the entire trial population, e.g. defined by a particular characteristic measured at baseline (e.g. a specific biomarker), this subset should be justified in this section.\nJustify whether the trial intervention is to be evaluated in paediatric participants, in adults unable to consent for themselves, other vulnerable participant populations, or those that may respond to the trial intervention differently (e.g., elderly, hepatic or renally impaired, or immunocompromised participants). ",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.1 Description of Trial Population and Rationale\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Lifestyle Restrictions": {
        "template": {
            "long_name": "Enter Lifestyle Restrictions",
            "short_name": "Lifestyle Restrictions",
            "optional": false,
            "section_number": "5.5",
            "section_title": "Lifestyle Restrictions",
            "instructions": []
        },
        "technical": {
            "name": "Lifestyle Restrictions",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the restrictions related to trial participant lifestyle such as diet, substance intake, and physical or other daily activities.",
            "guidance": "In the following subsections, describe any restrictions during the trial pertaining to lifestyle and/or diet, intake of caffeine, alcohol, or tobacco, or physical and other activities. If not applicable, include a statement that no restrictions are required. ",
            "conformance": "Conditional: If Level 3 subheadings are not used",
            "cardinality": "One to one",
            "relationship": "5.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.5\t Lifestyle Restrictions\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Meals and Dietary Restrictions": {
        "template": {
            "long_name": "Enter Meals and Dietary Restrictions",
            "short_name": "Meals and Dietary Restrictions",
            "optional": false,
            "section_number": "5.5.1",
            "section_title": "Meals and Dietary Restrictions",
            "instructions": []
        },
        "technical": {
            "name": "Meals and Dietary Restrictions",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the restrictions related to participant diet during the trial.",
            "guidance": "If applicable, describe any restrictions on diet (e.g., food and drink restrictions, timing of meals relative to dosing). ",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "5.5.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.5.1 Meals and Dietary Restrictions\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Physical Activity Restrictions": {
        "template": {
            "long_name": "Enter Physical Activity Restrictions",
            "short_name": "Physical Activity Restrictions",
            "optional": false,
            "section_number": "5.5.3",
            "section_title": "Physical Activity Restrictions",
            "instructions": []
        },
        "technical": {
            "name": "Physical Activity Restrictions",
            "data_type": "Text",
            "definition": "C17708\nFor review purpose, see definition of the controlled terminology below\nAny form of exercise or movement. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc.",
            "guidance": "If applicable, describe any restrictions on activity (e.g., in first-in-human trials, activity may be restricted by ensuring participants remain in bed for 4 to 6 hours after dosing). ",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "5.5.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.5.3 Physical Activity Restrictions\nConcept: C17708",
            "repeating": "No",
            "ct": []
        }
    },
    "Other Activity Restrictions": {
        "template": {
            "long_name": "Enter Other Activity Restrictions",
            "short_name": "Other Activity Restrictions",
            "optional": false,
            "section_number": "5.5.4",
            "section_title": "Other Activity Restrictions",
            "instructions": []
        },
        "technical": {
            "name": "Other Activity Restrictions",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn activity that is different than the one(s) previously specified or mentioned.",
            "guidance": "If applicable, describe restrictions on any other activity (e.g., blood or tissue donation, driving, heavy machinery use, or sun exposure).",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "5.5.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.5.4 Other Activity Restrictions\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Screen Failure": {
        "template": {
            "long_name": "Enter Screen Failure",
            "short_name": "Screen Failure",
            "optional": false,
            "section_number": "5.6",
            "section_title": "Screen Failure and Rescreening",
            "instructions": []
        },
        "technical": {
            "name": "Screen Failure",
            "data_type": "Text",
            "definition": "C49628\nFor review purpose, see definition of the controlled terminology below\nThe potential subject who does not meet eligibility (inclusion/exclusion) criteria during the screening period.",
            "guidance": "Describe screen failure and indicate how screen failure will be handled in the trial, including conditions and criteria upon which rescreening is acceptable. If applicable, indicate the circumstances and time window under which a repeat procedure is allowed for screen failure relating to specific inclusion/exclusion criteria for the trial.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.6 Screen Failure and Rescreening\nConcept: C49628",
            "repeating": "No",
            "ct": []
        }
    },
    "Rescreening": {
        "template": {
            "long_name": "Enter Rescreening",
            "short_name": "Rescreening",
            "optional": false,
            "section_number": "5.6",
            "section_title": "Screen Failure and Rescreening",
            "instructions": []
        },
        "technical": {
            "name": "Rescreening",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe process of active consideration of subjects for enrolment in a trial, for those potential subjects who have failed a prior screening attempt.",
            "guidance": "Describe screen failure and indicate how screen failure will be handled in the trial, including conditions and criteria upon which rescreening is acceptable. If applicable, indicate the circumstances and time window under which a repeat procedure is allowed for screen failure relating to specific inclusion/exclusion criteria for the trial.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.6 Screen Failure and Rescreening\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Arm Name": {
        "template": {
            "long_name": "Enter Arm Name",
            "short_name": "Arm Name",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Arm Name",
            "data_type": "Text",
            "definition": "C93729\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) for the arm.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to many; one to interventions for arm name",
            "relationship": "6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name \nConcept: C93729",
            "repeating": "Yes, repeatable for each arm name and intervention and use combination",
            "ct": []
        }
    },
    "Intervention Name": {
        "template": {
            "long_name": "Enter Intervention Name",
            "short_name": "Intervention Name",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Intervention Name",
            "data_type": "Text",
            "definition": "C177930\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) for the study intervention.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to arm name and arm type",
            "relationship": "6",
            "value": "Nonproprietary name or ponsor ",
            "business_rules": "Value Allowed: Yes\nRelationship: Arm name and intervention name, \nConcept: C177930",
            "repeating": "Yes, repeatable for each arm name and arm type",
            "ct": []
        }
    },
    "Description of Investigational Trial Intervention": {
        "template": {
            "long_name": "Enter Description of Investigational Trial Intervention",
            "short_name": "Description of Investigational Trial Intervention",
            "optional": false,
            "section_number": "6.1",
            "section_title": "Description of Investigational Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Description of Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the investigational trial intervention.",
            "guidance": "Describe the investigational trial intervention to be administered in each arm of the trial and for each period of the trial including route and mode of administration, dose, dosage regimen, duration of intervention, use, packaging and labelling. \nRefer to approved regional labelling, as appropriate. \nFor drug/device combination products, include details on the configuration and use of the device and device manufacturer. A device user manual may be referenced in this section.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.1 Description of Investigational Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rationale for Investigational Trial Intervention Dose and Regimen": {
        "template": {
            "long_name": "Enter Rationale for Investigational Trial Intervention Dose and Regimen",
            "short_name": "Rationale for Investigational Trial Intervention Dose and Regimen",
            "optional": false,
            "section_number": "6.2",
            "section_title": "Rationale for Investigational Trial Intervention Dose and Regimen",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Investigational Trial Intervention Dose and Regimen",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the choice of the trial intervention dose and dose regimen.",
            "guidance": "Provide a rationale for the selection of the dose(s) or dose range, pharmaceutical dose form, the route of administration, and dosing regimen of the investigational trial intervention, as applicable. This rationale should include relevant results from previous nonclinical studies and clinical trials that support selection of the dose and regimen. Discuss impact of differences in study population characteristics (for example, age, sex and/or race) which could lead to differences in pharmacokinetics and pharmacodynamics in this study as compared to previous studies. If applicable, justify any differences in dose regimen or therapeutic use relative to approved labelling. Describe prior trials and other information that support the dose and/or dose regimen of the investigational intervention.\nInclude a rationale for prospective dose adjustments incorporated in the trial, if any.\u00a0",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.2 Rationale for Investigational Trial Intervention Dose and Regimen\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Investigational Trial Intervention Administration": {
        "template": {
            "long_name": "Enter Investigational Trial Intervention Administration",
            "short_name": "Investigational Trial Intervention Administration",
            "optional": false,
            "section_number": "6.3",
            "section_title": "Investigational Trial Intervention Administration",
            "instructions": []
        },
        "technical": {
            "name": "Investigational Trial Intervention Administration",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the choice of the trial intervention dose and dose regimen.",
            "guidance": "Describe the detailed procedures for administration of each participant\u2019s dose of each investigational trial intervention. This may include the timing of dosing (for example, time of day, interval), the duration (for example, the length of time participants will be administered the investigational trial intervention), and the timing of dosing relative to meals. \nInclude any specific instructions to trial participants about when or how to prepare and take the dose(s) and how delayed or missed doses should be handled. \nDose escalation or cohort expansion as part of the overall design should be covered in Section 4.1 Description of Trial Design.\u00a0\n",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.3 Investigational Trial Intervention Administration\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Investigational Trial Intervention Dose Modification": {
        "template": {
            "long_name": "Enter Investigational Trial Intervention Dose Modification",
            "short_name": "Investigational Trial Intervention Dose Modification",
            "optional": false,
            "section_number": "6.4",
            "section_title": "Investigational Trial Intervention Dose Modification",
            "instructions": []
        },
        "technical": {
            "name": "Investigational Trial Intervention Dose Modification",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA change, alteration, or adjustment to the dose of a investigational trial intervention.",
            "guidance": "For each participant, describe any dose modifications allowed, including conditions for such dose modifications, particularly regarding failure to respond or safety concerns. State any minimum period required before a participant\u2019s dose might be raised to the next higher dose or dose range. Include whether it is permissible to start and stop treatment and how dose reductions (if permitted) are to be managed. \nInformation on stopping investigational trial intervention for participants due to safety/other reasons should be detailed in Section 7 Participant Discontinuation of Trial Intervention and Discontinuation or Withdrawal from Trial.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.4 Investigational Trial Intervention Dose Modification\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Management of Investigational Trial Intervention Overdose": {
        "template": {
            "long_name": "Enter Management of Investigational Trial Intervention Overdose",
            "short_name": "Management of Investigational Trial Intervention Overdose",
            "optional": false,
            "section_number": "6.5",
            "section_title": "Management of Investigational Trial Intervention Overdose",
            "instructions": []
        },
        "technical": {
            "name": "Management of Investigational Trial Intervention Overdose",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of how a potential investigational trial intervention overdose will be handled.",
            "guidance": "Describe what is meant by investigational trial intervention overdose. Provide any available information on managing the overdose and ensure it is consistent with the Investigator\u2019s Brochure or product labelling. Cross-references these documents as applicable. ",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "6.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.5 Management of Investigational Trial Intervention Overdose\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Storage and Handling of Investigational Trial Intervention": {
        "template": {
            "long_name": "Enter Storage and Handling of Investigational Trial Intervention",
            "short_name": "Storage and Handling of Investigational Trial Intervention",
            "optional": false,
            "section_number": "6.6.2",
            "section_title": "Storage and Handling of Investigational Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Storage and Handling of Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "C115525\nFor review purpose, see definition of the controlled terminology below\nThe safe handling, storage, distribution, and return of unused investigational trial intervention.",
            "guidance": "Describe storage and handling requirements (for example, protection from light, temperature, humidity) for the investigational trial intervention(s). For trials in which multi-dose vials are utilised, provide additional information regarding stability and expiration time after initial use (for example, the seal is broken).\u00a0\nState how the investigational trial intervention(s) will be provided to the Investigator. If applicable, describe the kits, packaging, or other material of the investigational trial intervention for blinding purposes.\u00a0\nIf the instructions are lengthy or complicated, it is acceptable to reference the package insert (if applicable) or include instructions in a separate document(s) provided to the site (for example, a pharmacy manual). If the latter, reference the separate documents. ",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "6.6.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.6.2 Storage and Handling of Investigational Trial Intervention\nConcept: C115525",
            "repeating": "No",
            "ct": []
        }
    },
    "Accountability of Investigational Trial Intervention": {
        "template": {
            "long_name": "Enter Accountability of Investigational Trial Intervention",
            "short_name": "Accountability of Investigational Trial Intervention",
            "optional": false,
            "section_number": "6.6.3",
            "section_title": "Accountability of Investigational Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Accountability of Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "C176267\nFor review purpose, see definition of the controlled terminology below\nThe act or process for documenting the storage, inventory tracking, and disposition of the investigational trial intervention.",
            "guidance": "Describe the method by which the accountability will be achieved, including trial intervention will be distributed and related details, including:\nhow and by whom the trial intervention will be distributed\nparticipation of a drug repository or pharmacy, if applicable, \nplans for disposal or return of unused product\nif applicable, plans for reconciliation of investigational trial intervention",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "6.6.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.6.3 Accountability of Trial Intervention\nConcept: C176267",
            "repeating": "No",
            "ct": []
        }
    },
    "Participant Assignment to Investigational Trial Intervention": {
        "template": {
            "long_name": "Enter Participant Assignment to Investigational Trial Intervention",
            "short_name": "Participant Assignment to Investigational Trial Intervention",
            "optional": false,
            "section_number": "6.7.1",
            "section_title": "Participant Assignment to Investigational Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Participant Assignment to Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe technique used to assign trial participants to a trial arm.",
            "guidance": "Describe the method of assigning participants to investigational trial intervention without being so specific that blinding or randomisation might be compromised. If assignment to investigational trial intervention is by randomisation, describe when randomisation occurs relative to screening. State that at enrollment, participant identification codes should be assigned. \nIf adaptive randomisation or other methods of covariate balancing/minimisation are employed, include a cross-reference to the methods of analysis in Section 10 Statistical Considerations. As applicable, details regarding the implementation of procedures to minimise bias should be described.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "6.7.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.7.1 Participant Assignment to Investigational Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Randomisation": {
        "template": {
            "long_name": "Enter Randomisation",
            "short_name": "Randomisation",
            "optional": false,
            "section_number": "6.7.2",
            "section_title": "{Randomisation}",
            "instructions": []
        },
        "technical": {
            "name": "Randomisation",
            "data_type": "Text",
            "definition": "C25196\nFor review purpose, see definition of the controlled terminology below\nThe process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. [ICH E6 1.48]",
            "guidance": "Describe the randomisation procedures (for example, central randomisation procedures), the method used to generate the randomisation schedule (for example, computer generated), the source of the randomisation schedule (for example, sponsor, investigator, or other), and whether IxRS will be used. To maintain the integrity of the blinding, do not include the block size. ",
            "conformance": "Conditional: when randomised trial",
            "cardinality": "One to one",
            "relationship": "6.7.2 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.7.2 Randomisation\nConcept: C25196",
            "repeating": "No",
            "ct": []
        }
    },
    "Emergency Unblinding at the Site": {
        "template": {
            "long_name": "Enter Emergency Unblinding at the Site",
            "short_name": "Emergency Unblinding at the Site",
            "optional": false,
            "section_number": "6.7.4",
            "section_title": "{Emergency Unblinding at the Site}",
            "instructions": []
        },
        "technical": {
            "name": "Emergency Unblinding at the Site",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the methodology used for unblinding of the trial treatment in the case of a sudden unforeseen crisis that requires immediate medical care of the participant. ",
            "guidance": "Describe the criteria for breaking the trial blind or participant code. Describe the circumstances in which the blinding would be broken for an individual or for all participants and who has responsibility. Include the procedure for emergency unblinding such as via IxRS or code envelopes as well as documentation of unblinding. Indicate to whom the intentional and unplanned unblinding should be reported.",
            "conformance": "Conditional: when blind trial ",
            "cardinality": "One to one",
            "relationship": "6.7.4 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.7.4 Emergency Unblinding at the Site\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rescue Therapy": {
        "template": {
            "long_name": "Enter Rescue Therapy",
            "short_name": "Rescue Therapy",
            "optional": false,
            "section_number": "6.9.2",
            "section_title": "{Rescue Therapy}",
            "instructions": []
        },
        "technical": {
            "name": "Rescue Therapy",
            "data_type": "Text",
            "definition": "C165835\nFor review purpose, see definition of the controlled terminology below\nMedicinal products identified in the protocol as those that may be administered to subjects when the efficacy of the investigational medicinal product (IMP) is not satisfactory, the effect of the IMP is too great and is likely to cause a hazard to the patient, or to manage an emergency situation. [After EU-CTR Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017]",
            "guidance": "List all permitted rescue medications, treatments, and/or procedures, including any relevant instructions about administration and any conditions for use. \nIf administration of rescue therapy leads to the temporary discontinuation of trial intervention or a participant\u2019s withdrawal from the trial, refer to Section 7 Participant Discontinuation of Trial Intervention and Withdrawal from Trial. ",
            "conformance": "Conditional: when any rescue therapies are defined ",
            "cardinality": "One to one",
            "relationship": "6.9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.9.2 Rescue Therapy\nConcept: C165835",
            "repeating": "No",
            "ct": []
        }
    },
    "Concomitant Therapy": {
        "template": {
            "long_name": "Enter Concomitant Therapy",
            "short_name": "Concomitant Therapy",
            "optional": false,
            "section_number": "6.10",
            "section_title": "Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Concomitant Therapy",
            "data_type": "Text",
            "definition": "C53630\nFor review purpose, see definition of the controlled terminology below\nAny pharmaceutical agent, other than the trial interventions, that is administered to or used by the subject prior to or during a specified time period.",
            "guidance": "Describe the concomitant medications, supplements, complementary and alternative therapies, treatments, and/or procedures which are prohibited or permitted during the trial and include details about when the information will be collected (for example, screening, all visits). \nThis section should be consistent with the medication restrictions in the inclusion/exclusion criteria. \nWhen appropriate to separate the content, subheadings may be used.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "6.10",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.10 Concomitant Therapy\nConcept: C53630",
            "repeating": "No",
            "ct": []
        }
    },
    "Prohibited Concomitant Therapy": {
        "template": {
            "long_name": "Enter Prohibited Concomitant Therapy",
            "short_name": "Prohibited Concomitant Therapy",
            "optional": false,
            "section_number": "6.10.1",
            "section_title": "{Prohibited Concomitant Therapy}",
            "instructions": []
        },
        "technical": {
            "name": "Prohibited Concomitant Therapy",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nConcomitant therapy that is banned from use in the trial.",
            "guidance": "If applicable, describe any prohibited concomitant therapy.",
            "conformance": "Conditional: when any prohibited concomitant therapies are defined",
            "cardinality": "One to one",
            "relationship": "6.10.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.10.1 Prohibited Concomitant Therapy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Permanent Discontinuation of Trial Intervention": {
        "template": {
            "long_name": "Enter Permanent Discontinuation of Trial Intervention",
            "short_name": "Permanent Discontinuation of Trial Intervention",
            "optional": false,
            "section_number": "7.1.1",
            "section_title": "Permanent Discontinuation of Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Permanent Discontinuation of Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to permanently discontinue the administration of trial intervention.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "7.1.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.1.1 Permanent Discontinuation of Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Temporary Discontinuation of Trial Intervention": {
        "template": {
            "long_name": "Enter Temporary Discontinuation of Trial Intervention",
            "short_name": "Temporary Discontinuation of Trial Intervention",
            "optional": false,
            "section_number": "7.1.2",
            "section_title": "Temporary Discontinuation of Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Temporary Discontinuation of Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to temporarily discontinue the administration of trial intervention.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "7.1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.1.2 Temporary Discontinuation of Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rechallenge": {
        "template": {
            "long_name": "Enter Rechallenge",
            "short_name": "Rechallenge",
            "optional": false,
            "section_number": "7.1.3",
            "section_title": "Rechallenge",
            "instructions": []
        },
        "technical": {
            "name": "Rechallenge",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to reintroduce previously withdrawn or temporarily discontinued medical intervention in the same patient.",
            "guidance": "Describe the criteria for rechallenge/restarting trial intervention, how to perform rechallenge, number of rechallenges allowed during the trial, and whether all, or specify which, assessments will be performed for the stated duration of the trial.\nIf rechallenge is not allowed, state this.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "7.1.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.1.3 Rechallenge\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Participant Discontinuation or Withdrawal from Trial": {
        "template": {
            "long_name": "Enter Participant Discontinuation or Withdrawal from Trial",
            "short_name": "Participant Discontinuation or Withdrawal from Trial",
            "optional": false,
            "section_number": "7.2",
            "section_title": "Participant Discontinuation or Withdrawal from the Trial",
            "instructions": []
        },
        "technical": {
            "name": "Participant Discontinuation or Withdrawal from Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe rationale for why the participant either discontinued or withdrawal from the trial.",
            "guidance": "Describe the criteria for participant discontinuation or withdrawal from the trial.\nDescribe the reason for withdrawal and the type of data to be collected for the final assessments with reference to the schedule of activities for the participant\u2019s end of study visit unless provided in another section. \nIn many cases, the only reason for a participant being considered withdrawn from the trial should be a participant\u2019s withdrawal of consent to continue to participate in the trial. All other participants, including those who discontinue treatment, should remain in the trial and continue to be followed to prevent missing data in important analyses. Refer to Section 10 Statistical Considerations for the data that must be collected for the trial estimands.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "7.2",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.2 Participants Discontinuation or Withdrawal from the Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial Assessments and Procedures Considerations": {
        "template": {
            "long_name": "Enter Trial Assessments and Procedures Considerations",
            "short_name": "Trial Assessments and Procedures Considerations",
            "optional": false,
            "section_number": "8.1",
            "section_title": "Trial Assessments and Procedures Considerations",
            "instructions": []
        },
        "technical": {
            "name": "Trial Assessments and Procedures Considerations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of general considerations applicable across trial assessments and procedures.",
            "guidance": "Describe general considerations applicable across trial assessments and procedures.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.1 Trial Assessments and Procedures Considerations\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Screening Assessments and Procedures": {
        "template": {
            "long_name": "Enter Screening Assessments and Procedures",
            "short_name": "Screening Assessments and Procedures",
            "optional": false,
            "section_number": "8.2",
            "section_title": "Screening/Baseline Assessments and Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Screening Assessments and Procedures",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial assessments and procedures related to the screening epoch of the trial.",
            "guidance": "Describe any assessments and procedures that are unique to screening/baseline (e.g., collection of data on participant characteristics, assessments/procedures performed for the purpose of determining eligibility or for stratification) in this section. Describe screening and baseline assessments and procedures separately when screening and baseline are different or performed at different visits.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "8.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.2 Screening/Baseline Assessments and Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Baseline Assessments and Procedures": {
        "template": {
            "long_name": "Enter Baseline Assessments and Procedures",
            "short_name": "Baseline Assessments and Procedures",
            "optional": false,
            "section_number": "8.2",
            "section_title": "Screening/Baseline Assessments and Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Baseline Assessments and Procedures",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial assessments and procedures related to the baseline epoch of the trial.",
            "guidance": "Describe any assessments and procedures that are unique to screening/baseline (e.g., collection of data on participant characteristics, assessments/procedures performed for the purpose of determining eligibility or for stratification) in this section. Describe screening and baseline assessments and procedures separately when screening and baseline are different or performed at different visits.",
            "conformance": "Conditional: when the Baseline Assessments and Procedures are different from Screening",
            "cardinality": "One to one",
            "relationship": "8.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.2 Screening/Baseline Assessments and Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Efficacy Assessments and Procedures": {
        "template": {
            "long_name": "Enter Efficacy Assessments and Procedures",
            "short_name": "Efficacy Assessments and Procedures",
            "optional": false,
            "section_number": "8.3",
            "section_title": "Efficacy Assessments and Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Efficacy Assessments and Procedures",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial assessments and procedures related to trial intervention efficacy.",
            "guidance": "Describe efficacy assessments and procedures in this section. Cross Section 8.7 Immunogenicity Assessments if immunogenicity assessments are used in efficacy determination.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.3 Efficacy Assessments and Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Safety Assessments and Procedures": {
        "template": {
            "long_name": "Enter Safety Assessments and Procedures",
            "short_name": "Safety Assessments and Procedures",
            "optional": false,
            "section_number": "8.4",
            "section_title": "Safety Assessments and Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Safety Assessments and Procedures",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the assessments and procedures related to participant safety within the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4 Safety Assessments and Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Physical Examination": {
        "template": {
            "long_name": "Enter Physical Examination",
            "short_name": "Physical Examination",
            "optional": false,
            "section_number": "8.4.1",
            "section_title": "{Physical Examination}",
            "instructions": []
        },
        "technical": {
            "name": "Physical Examination",
            "data_type": "Text",
            "definition": "C20989\nFor review purpose, see definition of the controlled terminology below\nThe procedures for a systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation.",
            "guidance": "Include any specific instructions for the collection and interpretation of physical examinations.",
            "conformance": "Conditional: when Physical Exams are required ",
            "cardinality": "One to one",
            "relationship": "8.4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.1 Physical Examination\nConcept: C20989",
            "repeating": "No",
            "ct": []
        }
    },
    "Vital Signs": {
        "template": {
            "long_name": "Enter Vital Signs",
            "short_name": "Vital Signs",
            "optional": false,
            "section_number": "8.4.2",
            "section_title": "{Vital Signs}",
            "instructions": []
        },
        "technical": {
            "name": "Vital Signs",
            "data_type": "Text",
            "definition": "C154628\nFor review purpose, see definition of the controlled terminology below \nThe procedures for measurements of the body's basic functions that provide insight into the health status of the person.",
            "guidance": "Include any specific instructions for the collection and interpretation of vital signs. ",
            "conformance": "Conditional: when Vital Signs are required",
            "cardinality": "One to one",
            "relationship": "8.4.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.2 Vital Signs\nConcept: C154628",
            "repeating": "No",
            "ct": []
        }
    },
    "Electrocardiograms": {
        "template": {
            "long_name": "Enter Electrocardiograms",
            "short_name": "Electrocardiograms",
            "optional": false,
            "section_number": "8.4.3",
            "section_title": "{Electrocardiograms}",
            "instructions": []
        },
        "technical": {
            "name": "Electrocardiograms",
            "data_type": "Text",
            "definition": "C168186\nFor review purpose, see definition of the controlled terminology below\nThe procedures for the recordings produced by the variations in electrical potential caused by electrical activity of the heart muscle and detected at the body surface, as a method for studying the action of the heart muscle.",
            "guidance": "Include any specific instructions for the collection, interpretation, and archiving of ECGs.",
            "conformance": "Conditional: when Electrocardiograms are required",
            "cardinality": "One to one",
            "relationship": "8.4.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.3 Electrocardiograms\nConcept: C168186",
            "repeating": "No",
            "ct": []
        }
    },
    "Pregnancy Testing": {
        "template": {
            "long_name": "Enter Pregnancy Testing",
            "short_name": "Pregnancy Testing",
            "optional": false,
            "section_number": "8.4.5",
            "section_title": "{Pregnancy Testing}",
            "instructions": []
        },
        "technical": {
            "name": "Pregnancy Testing",
            "data_type": "Text",
            "definition": "C92949\nFor review purpose, see definition of the controlled terminology below\nAny examination performed to assess if a female is gravid.",
            "guidance": "Include any specific instructions for the collection and interpretation of pregnancy testing. ",
            "conformance": "Conditional: when Pregnancy Testing is required",
            "cardinality": "One to one",
            "relationship": "8.4.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.5 Pregnancy Testing\nConcept: C92949",
            "repeating": "No",
            "ct": []
        }
    },
    "Suicidal Ideation and Behaviour Risk Monitoring": {
        "template": {
            "long_name": "Enter Suicidal Ideation and Behaviour Risk Monitoring",
            "short_name": "Suicidal Ideation and Behaviour Risk Monitoring",
            "optional": false,
            "section_number": "8.4.6",
            "section_title": "{Suicidal Ideation and Behaviour Risk Monitoring}",
            "instructions": []
        },
        "technical": {
            "name": "Suicidal Ideation and Behaviour Risk Monitoring",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of data collection procedures and analysis related to suicidal ideation and behaviour risk monitoring.",
            "guidance": "If the trial meets any of the criteria requiring suicidal ideation and behaviour risk monitoring by the guidance/guideline in each region, include justification for the need for suicidal ideation and behaviour risk monitoring in the study and add any specific instructions for the collection and interpretation of the assessment. In case this is an AESI in the study, justification should also be provided in Section 9.2.4 Adverse Events of Special Interest.",
            "conformance": "Conditional: when Suicidal Ideation and Behaviour Risk Monitoring are required",
            "cardinality": "One to one",
            "relationship": "8.4.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.6 Suicidal Ideation and Behaviour Risk Monitoring\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Pharmacokinetics": {
        "template": {
            "long_name": "Enter Pharmacokinetics",
            "short_name": "Pharmacokinetics",
            "optional": false,
            "section_number": "8.5",
            "section_title": "Pharmacokinetics",
            "instructions": []
        },
        "technical": {
            "name": "Pharmacokinetics",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in pharmacokinetic assessments within the trial.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "8.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.5 Pharmacokinetics\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Genetics and Pharmacogenomics": {
        "template": {
            "long_name": "Enter Genetics and Pharmacogenomics",
            "short_name": "Genetics and Pharmacogenomics",
            "optional": false,
            "section_number": "8.6.1",
            "section_title": "Genetics and Pharmacogenomics",
            "instructions": []
        },
        "technical": {
            "name": "Genetics and Pharmacogenomics",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in genetic and pharmacogenomic biomarker assessments within the trial.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "8.6.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.6.1 Genetics and Pharmacogenomics\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Pharmacodynamic Biomarkers": {
        "template": {
            "long_name": "Enter Pharmacodynamic Biomarkers",
            "short_name": "Pharmacodynamic Biomarkers",
            "optional": false,
            "section_number": "8.6.2",
            "section_title": "Pharmacodynamic Biomarkers",
            "instructions": []
        },
        "technical": {
            "name": "Pharmacodynamic Biomarkers",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in pharmacodynamic biomarker assessments within the trial.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "8.6.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.6.2 Pharmacodynamic Biomarkers\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Other Biomarkers": {
        "template": {
            "long_name": "Enter Other Biomarkers",
            "short_name": "Other Biomarkers",
            "optional": false,
            "section_number": "8.6.3",
            "section_title": "{Other Biomarkers}",
            "instructions": []
        },
        "technical": {
            "name": "Other Biomarkers",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in other biomarker assessments within the trial.",
            "guidance": "",
            "conformance": "Conditional: when Other Biomarkers are required",
            "cardinality": "One to one",
            "relationship": "8.6.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.6.3 Other Biomarkers\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Immunogenicity Assessments": {
        "template": {
            "long_name": "Enter Immunogenicity Assessments",
            "short_name": "Immunogenicity Assessments",
            "optional": false,
            "section_number": "8.7",
            "section_title": "Immunogenicity Assessments",
            "instructions": []
        },
        "technical": {
            "name": "Immunogenicity Assessments",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in immunogenicity assessments within the trial.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "8.7",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.7 Immunogenicity Assessments\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Medical Resource Utilisation and Health Economics": {
        "template": {
            "long_name": "Enter Medical Resource Utilisation and Health Economics",
            "short_name": "Medical Resource Utilisation and Health Economics",
            "optional": false,
            "section_number": "8.8",
            "section_title": "Medical Resource Utilisation and Health Economics",
            "instructions": []
        },
        "technical": {
            "name": "Medical Resource Utilisation and Health Economics",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about medical resource utilization and the health outcome measures, collection method and participant burden.",
            "guidance": "This section does not apply to COAs. Include this section only for any value evidence and outcomes assessments not included in either the efficacy or safety sections.\nDescribe the health outcome measures, collection method (e.g., diary, physician interview), and participant burden.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "8.8",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.8 Medical Resource Utilisation and Health Economics\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Definitions of Adverse Events": {
        "template": {
            "long_name": "Enter Definitions of Adverse Events",
            "short_name": "Definitions of Adverse Events",
            "optional": false,
            "section_number": "9.1.1",
            "section_title": "Definitions of Adverse Events",
            "instructions": []
        },
        "technical": {
            "name": "Definitions of Adverse Events",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of adverse events within the context of the trial. ",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one ",
            "relationship": "9.1.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.1.1 Definitions of Adverse Events\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Definitions of Serious Adverse Events": {
        "template": {
            "long_name": "Enter Definitions of Serious Adverse Events",
            "short_name": "Definitions of Serious Adverse Events",
            "optional": false,
            "section_number": "9.1.2",
            "section_title": "Definitions of Serious Adverse Events",
            "instructions": []
        },
        "technical": {
            "name": "Definitions of Serious Adverse Events",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of serious adverse events within the context of the trial.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one ",
            "relationship": "9.1.2",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.1.2 Definitions of Serious Adverse Events\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Definition of Medical Device Product Complaints": {
        "template": {
            "long_name": "Enter Definition of Medical Device Product Complaints",
            "short_name": "Definition of Medical Device Product Complaints",
            "optional": false,
            "section_number": "9.1.3.1",
            "section_title": "{Definition of Medical Device Product Complaints}",
            "instructions": []
        },
        "technical": {
            "name": "Definition of Medical Device Product Complaints",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of medical device product complaints within the context of the trial.",
            "guidance": "N/A",
            "conformance": "Conditional: when there is Medical Device Product Complaints",
            "cardinality": "One to one",
            "relationship": "9.1.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.1.3 Definition of Medical Device Product Complaints\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Situational Scope": {
        "template": {
            "long_name": "Situational Scope",
            "short_name": "Situational Scope",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Situational Scope",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the specific circumstances and context in which safety events are collected and monitored.",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type",
            "ct": []
        }
    },
    "Reportable Period Start": {
        "template": {
            "long_name": "Reportable Period Start",
            "short_name": "Reportable Period Start",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Reportable Period Start",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date on which reporting will begin for trial related events such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events.",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type ",
            "ct": []
        }
    },
    "Reportable Period End": {
        "template": {
            "long_name": "Reportable Period End",
            "short_name": "Reportable Period End",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Reportable Period End",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date on which reporting will cease for trial related events such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events.",
            "guidance": "N/A",
            "conformance": "Optional ",
            "cardinality": "One to one",
            "relationship": "9.2 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type",
            "ct": []
        }
    },
    "Method for Reporting": {
        "template": {
            "long_name": "Method for Reporting",
            "short_name": "Method for Reporting",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Method for Reporting",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the technique by which trial related events, such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events, are reported to the sponsor and/or regulatory authority.",
            "guidance": "N/A",
            "conformance": "Optional ",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type",
            "ct": []
        }
    },
    "Backup Method for Reporting": {
        "template": {
            "long_name": "Backup Method for Reporting",
            "short_name": "Backup Method for Reporting",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Backup Method for Reporting",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of alternative techniques by which trial related events, such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events, are reported to the sponsor and/or regulatory authority.",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type",
            "ct": []
        }
    },
    "Identification": {
        "template": {
            "long_name": "Enter Identification",
            "short_name": "Identification",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Identification",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA summary of the identification, recording, assessments of severity and causality, and follow-up of adverse events, serious adverse events, pregnancy and postpartum events, and medical device product complaints.",
            "guidance": "Specify .",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.2 Collection Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Severity": {
        "template": {
            "long_name": "Enter Severity",
            "short_name": "Severity",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Severity",
            "data_type": "Text",
            "definition": "C25676\nFor review purpose, see definition of the controlled terminology below \nThe evaluation of the intensity (severity) of an event.",
            "guidance": "Specify the intensity rating categories/scale.",
            "conformance": "Required ",
            "cardinality": "One to one ",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Severity\nConcept: C25676",
            "repeating": "No",
            "ct": []
        }
    },
    "Causality": {
        "template": {
            "long_name": "Enter Causality",
            "short_name": "Causality",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Causality",
            "data_type": "Text",
            "definition": "C82552\nFor review purpose, see definition of the controlled terminology below\nThe evaluation of the degree of causality (attributability) between a trial intervention and an event.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one ",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Causality\nConcept: C82552",
            "repeating": "No ",
            "ct": []
        }
    },
    "Recording": {
        "template": {
            "long_name": "Enter Recording",
            "short_name": "Recording",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Recording",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description for the procedures used to document an event.",
            "guidance": "Specify procedures for recording.",
            "conformance": "Required ",
            "cardinality": "One to one ",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Recording\nConcept: CNEW",
            "repeating": "No ",
            "ct": []
        }
    },
    "Reporting": {
        "template": {
            "long_name": "Enter Reporting",
            "short_name": "Reporting",
            "optional": false,
            "section_number": "9.2.3",
            "section_title": "Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Reporting",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the method and timelines for reporting an event to the sponsor.",
            "guidance": "Specify the reporting method (e.g., an electronic data collection tool or a paper CRF) and reporting timeline to the Sponsor.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "9.2.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.3 Reporting\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Regulatory Reporting Requirements": {
        "template": {
            "long_name": "Enter Regulatory Reporting Requirements",
            "short_name": "Regulatory Reporting Requirements",
            "optional": false,
            "section_number": "9.2.3.1",
            "section_title": "Regulatory Reporting Requirements",
            "instructions": []
        },
        "technical": {
            "name": "Regulatory Reporting Requirements",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the requirements for the sponsor/designee to report a serious adverse event, including the criteria for reporting, to the relevant regulatory authority.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "9.2.3.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.3.1 Regulatory Reporting Requirements\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Participants Who Become Pregnant During the Trial": {
        "template": {
            "long_name": "Enter Participants Who Become Pregnant During the Trial",
            "short_name": "Participants Who Become Pregnant During the Trial",
            "optional": false,
            "section_number": "9.3.1",
            "section_title": "{Participants Who Become Pregnant During the Trial}",
            "instructions": []
        },
        "technical": {
            "name": "Participants Who Become Pregnant During the Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the processes and procedures used to collect pregnancy data for a trial participant who becomes pregnant while the participant is in the trial, as well as data collection about the child.",
            "guidance": "",
            "conformance": "",
            "cardinality": "One to one",
            "relationship": "9.3.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.3.1 Participants Who Become Pregnant During the Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Special Safety Situations": {
        "template": {
            "long_name": "Enter Special Safety Situations",
            "short_name": "Special Safety Situations",
            "optional": false,
            "section_number": "9.4",
            "section_title": "Special Safety Situations",
            "instructions": []
        },
        "technical": {
            "name": "Special Safety Situations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA characterization or classification of those trial specific situations that are associated with the trial intervention(s) and require regulatory reporting, but that do not qualify as an adverse event or serious adverse event for the given trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.4 Special Safety Situations\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "General Considerations": {
        "template": {
            "long_name": "Enter General Considerations",
            "short_name": "General Considerations",
            "optional": false,
            "section_number": "10.1",
            "section_title": "General Considerations",
            "instructions": []
        },
        "technical": {
            "name": "General Considerations",
            "data_type": "Text",
            "definition": "C164387\nFor review purpose, see definition of the controlled terminology below\nCareful thought or deliberation related to the planned conduct of statistical analyses within the context of the trial.",
            "guidance": "Provide statements relevant to statistical considerations in general. For example, this might include statements indicating whether there is a separate statistical analysis plan, which general summary statistics will be provided, and when the analyses will be conducted (e.g. \u201cThe analysis will be conducted on all participant data at the time the trial ends.\u201d).",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.1 General Considerations, 10 STATISTICAL CONSIDERATIONS and Table of Contents\nConcept: C164387",
            "repeating": "No",
            "ct": []
        }
    },
    "Analysis Sets": {
        "template": {
            "long_name": "Enter Analysis Sets",
            "short_name": "Analysis Sets",
            "optional": false,
            "section_number": "10.2",
            "section_title": "Analysis Sets",
            "instructions": []
        },
        "technical": {
            "name": "Analysis Sets",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the set of participants whose data are to be included in the analyses. ",
            "guidance": "Describe analysis sets to be considered at the trial level, i.e. the set of participants whose data are to be included in the analyses. For each analysis described in Section 10, it should be clear which analysis set should be used.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.2 Analysis Sets, 10 STATISTICAL CONSIDERATIONS and Table of Contents\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Analyses of Demographics and Other Baseline Variables": {
        "template": {
            "long_name": "Enter Analyses of Demographics and Other Baseline Variables",
            "short_name": "Analyses of Demographics and Other Baseline Variables",
            "optional": false,
            "section_number": "10.3",
            "section_title": "Analyses of Demographics and Other Baseline Variables",
            "instructions": []
        },
        "technical": {
            "name": "Analyses of Demographics and Other Baseline Variables",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of analyses relevant to variables at baseline, for example demographics, related to the trial.",
            "guidance": "Describe the summary statistics that will be used to describe the distribution of demographic and other relevant variables at baseline. Specify the timing of the measurement of the variables (e.g., at inclusion in the trial; before, or at randomisation). Relevant variables include but are not limited to: stratification variables specified in Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding, covariates for the statistical models specified in Section 10.4 Analyses Associated with the Primary Objective(s), other suspected predictive or prognostic variables, and variables used for planned subgroup analyses.\n",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.3 Analyses of Demographics and Other Baseline Variables, 10 STATISTICAL CONSIDERATIONS and Table of Contents\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Sensitivity Analysis": {
        "template": {
            "long_name": "Enter Sensitivity Analysis",
            "short_name": "Sensitivity Analysis",
            "optional": false,
            "section_number": "10.4.1.4",
            "section_title": "{Sensitivity Analysis}",
            "instructions": []
        },
        "technical": {
            "name": "Sensitivity Analysis",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the series of analyses conducted to explore the robustness of inferences from the main estimator to deviations from its underlying modelling assumptions and limitations in the data.",
            "guidance": "Describe any supplementary analysis, if applicable. Supplementary analyses are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
            "conformance": "Conditional: when there is Seconday Objective and sensitivity Analysis for a Secondary objective",
            "cardinality": "One to one",
            "relationship": "\n10.5.X.4",
            "value": "Text",
            "business_rules": "Value Allowed Yes\nRelationship: 10.5.4 Sensitivity Analysis\nConcept: CNEW",
            "repeating": "",
            "ct": []
        }
    },
    "Supplementary Analysis": {
        "template": {
            "long_name": "Enter Supplementary Analysis",
            "short_name": "Supplementary Analysis",
            "optional": false,
            "section_number": "10.4.1.5",
            "section_title": "{Supplementary Analysis}",
            "instructions": []
        },
        "technical": {
            "name": "Supplementary Analysis",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses that are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
            "guidance": "Describe any supplementary analysis if applicable. Supplementary analyses are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
            "conformance": "Conditional: when there Supplementary Analysis for a Secondary objective",
            "cardinality": "One to one",
            "relationship": "\n10.5.X.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
            "repeating": "",
            "ct": []
        }
    },
    "Safety Analyses": {
        "template": {
            "long_name": "Enter Safety Analyses",
            "short_name": "Safety Analyses",
            "optional": false,
            "section_number": "10.7",
            "section_title": "Safety Analyses",
            "instructions": []
        },
        "technical": {
            "name": "Safety Analyses",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses of relevant safety variables, including adverse events of special interest.",
            "guidance": "If safety is a primary and/or secondary objective, describe the corresponding safety analyses in the appropriate section above (Section 10.4 Analyses Associated with the Primary Objective(s) or Section 10.5 Analyses Associated with the Secondary Objective[s]). In this section, describe statistical methods that will be used to analyse relevant safety outcomes, including any AESI. This should typically include specification of a measure to estimate risk within treatment arms, a measure to compare risks across treatment arms, and a measure of statistical uncertainty around the comparison such as a confidence interval.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.7",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.7 Safety Analyses\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Other Analyses": {
        "template": {
            "long_name": "Enter Other Analyses",
            "short_name": "Other Analyses",
            "optional": false,
            "section_number": "10.8",
            "section_title": "Other Analyses",
            "instructions": []
        },
        "technical": {
            "name": "Other Analyses",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses that are different than the one(s) previously specified or mentioned.",
            "guidance": "Describe other analyses not included in Sections 10.3-10.8, such as subgroup analyses.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.8",
            "value": "Text ",
            "business_rules": "Value AllowedYes\nRelationship: 10.8 Other Analyses,Concept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Interim Analyses": {
        "template": {
            "long_name": "Enter Interim Analyses",
            "short_name": "Interim Analyses",
            "optional": false,
            "section_number": "10.9",
            "section_title": "Interim Analyses",
            "instructions": []
        },
        "technical": {
            "name": "Interim Analyses",
            "data_type": "Text",
            "definition": "C142582\nFor review purpose, see definition of the controlled terminology below\nA textual description of any analysis intended to compare treatment arms with respect to efficacy or safety at any time prior to the formal completion of a trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.9",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.9 Interim Analyses\nConcept: C142582",
            "repeating": "Yes, repeatable for each interim",
            "ct": []
        }
    },
    "Multiplicity Adjustments": {
        "template": {
            "long_name": "Enter Multiplicity Adjustments",
            "short_name": "Multiplicity Adjustments",
            "optional": false,
            "section_number": "10.10",
            "section_title": "Multiplicity Adjustments",
            "instructions": []
        },
        "technical": {
            "name": "Multiplicity Adjustments",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical adjustments needed to limit the probability of false positive findings in trials where there are multple simultaneous hypotheses.",
            "guidance": "Multiple testing procedures may be needed to limit the probability of false positive findings in a trial. Reasons for carrying out multiple statistical tests include - but are not restricted to - multiple endpoints, multiple treatment groups, multiple hypotheses, subgroups, different statistical methods, etc.\nDescribe any approaches to multiplicity control for the trial. This description might go beyond the analysis of primary objectives.\nSpecify the statistical approach to control the overall type I error rate as well as the (adjusted) significance levels to test specific hypotheses, as applicable. Clarify whether the tests/confidence intervals are one- or two-sided.\nState the circumstances under which a study will be considered to have met its primary objective(s). For example, in a study with two primary efficacy endpoints, this section should state whether the study would be expected to provide evidence on at least one or on both of the endpoints in order to confirm the efficacy of the treatment.\nFor some statistical approaches it might be helpful to include a graphical depiction, as visualisation will be helpful for understanding, coupled with the clinical translation of the mathematical choices.\nDetails regarding Interim Analyses should be provided in section 10.9.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.10",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship:10.10 Multiplicity Adjustments\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Sample Size Determination": {
        "template": {
            "long_name": "Enter Sample Size Determination",
            "short_name": "Sample Size Determination",
            "optional": false,
            "section_number": "10.11",
            "section_title": "Sample Size Determination",
            "instructions": []
        },
        "technical": {
            "name": "Sample Size Determination",
            "data_type": "Text",
            "definition": "C115467\nFor review purpose, see definition of the controlled terminology below\nA statistical calculation to determine the number of subjects required for the primary analysis, which should be large enough to provide a reliable answer to the questions addressed and should be determined by the primary objective of the trial. If the sample size is determined on some other basis, then this should be made clear and justified.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.11",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.11 Sample Size Determination,\nConcept: C115467",
            "repeating": "No",
            "ct": []
        }
    },
    "Regulatory and Ethical Considerations": {
        "template": {
            "long_name": "Enter Regulatory and Ethical Considerations",
            "short_name": "Regulatory and Ethical Considerations",
            "optional": false,
            "section_number": "11.1",
            "section_title": "Regulatory and Ethical Considerations",
            "instructions": []
        },
        "technical": {
            "name": "Regulatory and Ethical Considerations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nCareful thought or deliberation related to the regulatory and ethical aspects of the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one ",
            "relationship": "11.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.1 Regulatory and Ethical Considerations\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial Oversight ": {
        "template": {
            "long_name": "Enter Trial Oversight ",
            "short_name": "Trial Oversight ",
            "optional": false,
            "section_number": "11.2",
            "section_title": "Trial Oversight",
            "instructions": [
                "OR"
            ]
        },
        "technical": {
            "name": "Trial Oversight ",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the planned processes and procedures to govern and conduct a clinical trial in order to protect the rights, safety and welfare of the trial participants.",
            "guidance": "Concisely summarize the trial oversight listing the investigator and sponsor responsibilities not covered in other sections of the protocol which are essential for the operations of the trial, specifying the ones related to quality assurance.\nif not using below optional subheadings",
            "conformance": "",
            "cardinality": "One to one",
            "relationship": "11.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.2 Trial Oversight\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Investigator Responsibilities": {
        "template": {
            "long_name": "Enter Investigator Responsibilities",
            "short_name": "Investigator Responsibilities",
            "optional": false,
            "section_number": "11.2.1",
            "section_title": "Investigator Responsibilities",
            "instructions": []
        },
        "technical": {
            "name": "Investigator Responsibilities",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the investigator with respect to the trial.",
            "guidance": "",
            "conformance": "Optional ",
            "cardinality": "One to one ",
            "relationship": "11.2.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.2.1 Investigator Responsibilities\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Sponsor Responsibilities": {
        "template": {
            "long_name": "Enter Sponsor Responsibilities",
            "short_name": "Sponsor Responsibilities",
            "optional": true,
            "section_number": "11.2.2",
            "section_title": "Sponsor Responsibilities",
            "instructions": []
        },
        "technical": {
            "name": "Sponsor Responsibilities",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the sponsor with respect to the trial.",
            "guidance": "",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "11.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.2.2 Sponsor Responsibilities\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Description of Informed Consent Process": {
        "template": {
            "long_name": "Enter Description of Informed Consent Process",
            "short_name": "Description of Informed Consent Process",
            "optional": false,
            "section_number": "11.3",
            "section_title": "Informed Consent Process",
            "instructions": []
        },
        "technical": {
            "name": "Description of Informed Consent Process",
            "data_type": "Text",
            "definition": "C184390\nFor review purpose, see definition of the controlled terminology below\nThe procedure by which informed consent is obtained and documented by means of a written, signed, and dated informed consent form. This process may include obtaining assent from participants with legally authorised representatives.",
            "guidance": "Specify the key elements of the informed consent process, including any special needs and how these are addressed (e.g., assent, capacity, legally acceptable representative, adolescents who may reach age of majority during the trial, pregnant participants and pregnant partners of participants).",
            "conformance": "Required",
            "cardinality": "One to one ",
            "relationship": "11.3",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3 Informed Consent Process\nConcept: C184390",
            "repeating": "No",
            "ct": []
        }
    },
    "Description of Assent Process": {
        "template": {
            "long_name": "Enter Description of Assent Process",
            "short_name": "Description of Assent Process",
            "optional": true,
            "section_number": "11.3",
            "section_title": "Informed Consent Process",
            "instructions": [
                "If enrollment in the trial may occur during an emergency in which the participant or their legally acceptable representative is not able or available to give consent, describe the consent process."
            ]
        },
        "technical": {
            "name": "Description of Assent Process",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA  of the assent process for those individuals unable to give informed consent on their own behalf, to participate in the trial.",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "11.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3 Informed Consent Process\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Description of Emergency Consent Process": {
        "template": {
            "long_name": "Enter Description of Emergency Consent Process",
            "short_name": "Description of Emergency Consent Process",
            "optional": true,
            "section_number": "11.3",
            "section_title": "Informed Consent Process",
            "instructions": []
        },
        "technical": {
            "name": "Description of Emergency Consent Process",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA type of informed consent process that may occur during an emergency situation in which the participant or their legally authorised representative is not available to give consent.",
            "guidance": "If enrollment in the trial may occur during an emergency in which the participant or their legally acceptable representative is not able or available to give consent, describe the consent process.",
            "conformance": "Optional",
            "cardinality": "One to one ",
            "relationship": "11.3",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3 Informed Consent Process\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Committees": {
        "template": {
            "long_name": "Enter Committees",
            "short_name": "Committees",
            "optional": false,
            "section_number": "11.4",
            "section_title": "Committees",
            "instructions": []
        },
        "technical": {
            "name": "Committees",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the type and administrative structure of any committee associated with the trial.",
            "guidance": "Briefly describe the administrative structure of committees that will be reviewing data while the trial is ongoing, and the type of committee (e.g., Dose Escalation Committee, Data Monitoring Committee or Data Safety Monitoring Board). Note that specific details may be required depending on local law or regulation. If applicable, Committee Charters may be cross-referenced. If no committees are applicable, state \u201c applicable.\u201d",
            "conformance": "Required",
            "cardinality": "One to one ",
            "relationship": "11.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.4 Committees\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Insurance and Indemnity": {
        "template": {
            "long_name": "Enter Insurance and Indemnity",
            "short_name": "Insurance and Indemnity",
            "optional": false,
            "section_number": "11.5",
            "section_title": "Insurance and Indemnity",
            "instructions": []
        },
        "technical": {
            "name": "Insurance and Indemnity",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise summary of the arrangements for participants insurance and indemnity as required by the applicable regulatory body.",
            "guidance": "Concisely summarize the arrangements for participants insurance and indemnity if not addressed in a separate agreement, if required by the applicable regulatory requirements.",
            "conformance": "Required",
            "cardinality": "One to ",
            "relationship": "11.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.5 Insurance and Indemnity\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Data Governance": {
        "template": {
            "long_name": "Enter Data Governance",
            "short_name": "Data Governance",
            "optional": false,
            "section_number": "11.7",
            "section_title": "Data Governance",
            "instructions": []
        },
        "technical": {
            "name": "Data Governance",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the key processes to ensure data integrity, traceability and security, in order to enable accurate collection, reporting, monitoring, transfer, retention, access and publication.",
            "guidance": "\n",
            "conformance": "Required",
            "cardinality": "One to one ",
            "relationship": "11.7",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.7 Data Governance\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Source Data Introduction": {
        "template": {
            "long_name": "Enter Source Data Introduction",
            "short_name": "Source Data Introduction",
            "optional": false,
            "section_number": "11.9",
            "section_title": "Source Data",
            "instructions": []
        },
        "technical": {
            "name": "Source Data Introduction",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of trial-related source data including the importance of source data maintenance and expectations for data traceability.",
            "guidance": "Establish the importance of source data and expectation for traceability of transcribed information back to source. Delineate expectations for investigators (e.g., maintain source data at the site, ensure availability of current records) and trial monitors (e.g., verify CRF data relative to source, ensure that safety of participants is being protected and that conduct is in accordance with GCP). what constitutes source data and its origin or provide a reference to the location of , if contained in a separate document, such as a monitoring guideline or source data acknowledgement).\nDescribe the provision for direct access to source data and documents enabling clinical trial-related monitoring, audits and regulatory inspections, if not included in separate agreement(s).",
            "conformance": "Required",
            "cardinality": "One to one ",
            "relationship": "11.",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.Source Data\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Investigator Expectations for Source Data": {
        "template": {
            "long_name": "Enter Investigator Expectations for Source Data",
            "short_name": "Investigator Expectations for Source Data",
            "optional": false,
            "section_number": "11.9",
            "section_title": "Source Data",
            "instructions": []
        },
        "technical": {
            "name": "Investigator Expectations for Source Data",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the investigator with respect to maintaining and ensuring availability of the source data.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one ",
            "relationship": "11.",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.Source Data\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial Monitor Expectations for Source Data": {
        "template": {
            "long_name": "Enter Trial Monitor Expectations for Source Data",
            "short_name": "Trial Monitor Expectations for Source Data",
            "optional": false,
            "section_number": "11.9",
            "section_title": "Source Data",
            "instructions": []
        },
        "technical": {
            "name": "Trial Monitor Expectations for Source Data",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the trial monitor with respect to maintaining and ensuring availability of the source data.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one ",
            "relationship": "11.",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.Source Data\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Protocol Deviations": {
        "template": {
            "long_name": "Enter Protocol Deviations",
            "short_name": "Protocol Deviations",
            "optional": false,
            "section_number": "11.10",
            "section_title": "Protocol Deviations",
            "instructions": []
        },
        "technical": {
            "name": "Protocol Deviations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of plans for detecting, reviewing, and reporting any deviations from the protocol.",
            "guidance": "Describe plans for detecting, reviewing, and reporting any deviations from the protocol or include reference to a separate document.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship:  Protocol Deviations\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Decision Rights for Site Closure": {
        "template": {
            "long_name": "Enter Decision Rights for Site Closure",
            "short_name": "Decision Rights for Site Closure",
            "optional": false,
            "section_number": "11.11",
            "section_title": "Early Site Closure",
            "instructions": [
                "List the criteria for early closure of a site by the sponsor or investigator."
            ]
        },
        "technical": {
            "name": "Decision Rights for Site Closure",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the legal principles of entitlement for the sponsor to close a trial site, or for the investigator to initiate the closure of a trial site.",
            "guidance": "List the sponsor\u2019s rights to close a site early. Likewise, list the investigator\u2019s rights to initiate early site closure.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship:  Early Site Closure\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Criteria for Early Closure": {
        "template": {
            "long_name": "Enter Criteria for Early Closure",
            "short_name": "Criteria for Early Closure",
            "optional": false,
            "section_number": "11.11",
            "section_title": "Early Site Closure",
            "instructions": [
                "List the responsibilities of the sponsor and investigator following early site closure, such as informing the ethics committee(s), and prompt notification of the participant and their transition to appropriate therapy and/or follow-up."
            ]
        },
        "technical": {
            "name": "Criteria for Early Closure",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to close a trial site prematurely.\n",
            "guidance": "List the criteria for early closure of a site by the sponsor or investigator.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship:  Early Site Closure\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Responsibilities Following Early Site Closure": {
        "template": {
            "long_name": "Enter Responsibilities Following Early Site Closure",
            "short_name": "Responsibilities Following Early Site Closure",
            "optional": false,
            "section_number": "11.11",
            "section_title": "Early Site Closure",
            "instructions": []
        },
        "technical": {
            "name": "Responsibilities Following Early Site Closure",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe responsibilities of the sponsor and/or investigator following an unplanned early termination or suspension of the trial at an individual site.",
            "guidance": "List the responsibilities of the sponsor and investigator following early site closure, such as informing the ethics committee(s), and prompt notification of the participant and their transition to appropriate therapy and/or follow-up.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship:  Early Site Closure\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Clinical Laboratory Tests": {
        "template": {
            "long_name": "Enter Clinical Laboratory Tests",
            "short_name": "Clinical Laboratory Tests",
            "optional": false,
            "section_number": "12.1",
            "section_title": "Clinical Laboratory Tests",
            "instructions": []
        },
        "technical": {
            "name": "Clinical Laboratory Tests",
            "data_type": "Text",
            "definition": "C25294\nFor review purpose, see definition of the controlled terminology below\nAny procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.",
            "guidance": "Specify which laboratory parameters should be included in each clinical laboratory assessment panel (e.g., for haematology, chemistry, urinalysis). A tabular presentation for such information is common. If applicable, include equations and references for locally calculated laboratory results. \nIf not applicable, retain heading and enter \u201cNot applicable.\u201d",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "12.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.1 Clinical Laboratory Tests\nConcept: C25294",
            "repeating": "No",
            "ct": []
        }
    },
    "Amendment Identifier": {
        "template": {
            "long_name": "Enter Amendment Identifier",
            "short_name": "Amendment Identifier",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "Amendment Identifier",
            "data_type": "Text or \u201cOriginal Protocol\u201d",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to uniquely identif a protocol amendment.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Text or \u201cOriginal Protocol\u201d ",
            "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading \u201cDocument\u201d\nConcept: CNEW",
            "repeating": "Yes, reuse from the title page",
            "ct": []
        }
    },
    "Glossary of Terms and Abbreviations": {
        "template": {
            "long_name": "Enter Glossary of Terms and Abbreviations",
            "short_name": "Glossary of Terms and Abbreviations",
            "optional": false,
            "section_number": "13",
            "section_title": "Appendix: Glossary of Terms and Abbreviations",
            "instructions": []
        },
        "technical": {
            "name": "Glossary of Terms and Abbreviations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA collection of abbreviations (a shortened form of a word or phrase) and definitions (a concise explanation of the meaning of a word or phrase or symbol).",
            "guidance": "Define abbreviations and other terms used in the protocol. A tabular presentation is common and may serve as the definition at first use.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "13",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 13 APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "References": {
        "template": {
            "long_name": "Enter References",
            "short_name": "References",
            "optional": false,
            "section_number": "14",
            "section_title": "Appendix: References",
            "instructions": []
        },
        "technical": {
            "name": "References",
            "data_type": "Text",
            "definition": "C184397\nFor review purpose, see definition of the controlled terminology below\nThe curated list of sources that are cited within the reference section of the document.",
            "guidance": "References should be listed in a common format that includes all relevant information to identify the source and date published. If not published, this should be clearly indicated. ",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "14 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 14 APPENDIX: REFERENCES\nConcept: C184397",
            "repeating": "No",
            "ct": []
        }
    }
}